RxDoctor Payments Data

Stephen Hurlbut, MD

Neurology · Bedford, TXNPI 1699750836

Payments from drug & device makers

$6,467in general payments, 2019–2025

Across 323 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$530
  • TG Therapeutics, Inc.$405
  • EMD Serono, Inc.$282
  • Biogen$264
  • Lilly USA, LLC$238
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$6,32798%
  • Education$1402%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,467 in reported general payments places this provider in the 60th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$478,094
Medicare patients
540
Services billed
8,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5021$285,133
Gamunex-CImmune Globul G/Gly/Iga Avg 4642$235,619
TecfideraDimethyl Fumarate18$157,407
Avonex (4 Pack)Interferon Beta-1a12$115,038
AustedoDeutetrabenazine20$108,501
QuliptaAtogepant78$97,172
Aimovig AutoinjectorErenumab-Aooe55$44,782
Nurtec OdtRimegepant Sulfate34$44,156
RytaryCarbidopa/Levodopa69$39,145
AptiomEslicarbazepine Acetate11$37,667
Dalfampridine ErDalfampridine27$21,143
Emgality SyringeGalcanezumab-Gnlm29$20,279
DepakoteDivalproex Sodium20$15,544
UbrelvyUbrogepant15$14,727
Gabapentin575$12,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Avonex (4 Pack)$264$272,44530 claims
Grifols USA, LLCGamunex-C$65$235,61942 claims
AbbVieQulipta, Ubrelvy$1,784$111,89993 claims
Teva Pharmaceuticals USA, Inc.Austedo$530$108,50120 claims
PfizerNurtec Odt, Dilantin$175$47,24246 claims
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil, Pyridostigmine Bromide$63$45,906156 claims
Sunovion Pharmaceuticals Inc.Aptiom$150$37,66711 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$19$10,16420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,246 neurology providers in Texas.

Other neurology in Bedford

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →